Trial
NCT05284032
A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)
Early Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Firas El Chaer, MD
Collaborators
—
Condition
Platelet Refractoriness
Intervention
isatuximab 10 mg/kg
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-31